Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Johns Hopkins University
With
National Institute of Allergy and Infectious Diseases (NIAID)
American College of Chest Physicians
This research is being done to better understand several important aspects of treatment of Mycobacterium avium complex (MAC) lung infections using an early bactericidal activity (EBA) study design. MAC is an environmental bacteria that can cause chronic lung infection. Early bactericidal activity is the amount of bacterial killing that occurs during the first few weeks of antibiotic treatment. By collecting information about the EBA of azithromycin for MAC, the investigators will quantify the efficacy of azithromycin against pulmonary MAC.
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥18 years
Isolation of M. avium intracellulare complex from a respiratory specimen in the preceding 6 months
Fulfill American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) criteria for MAC lung disease
Intention by the treating clinician to treat for MAC lung disease.
Ability to produce a sputum sample of at least 10mL in a 16 hour period
Signed informed consent by the subject
You may not be if
Prior treatment for pulmonary MAC within the past 6 months
Pregnancy
HIV with a cluster of differentiation 4 (CD4) \<350
History of solid organ or hematologic transplant
Contraindication to azithromycin
Has any other condition that, in the opinion of the PI, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
